IN2013MU01208A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01208A
IN2013MU01208A IN1208MU2013A IN2013MU01208A IN 2013MU01208 A IN2013MU01208 A IN 2013MU01208A IN 1208MU2013 A IN1208MU2013 A IN 1208MU2013A IN 2013MU01208 A IN2013MU01208 A IN 2013MU01208A
Authority
IN
India
Prior art keywords
present
xanthophylls
composition
zeaxanthin
neurodegenerative disorders
Prior art date
Application number
Other languages
English (en)
Inventor
Deshpande Dr Jayant
J Shankaranarayanan
Original Assignee
Omniactive Health Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/780,595 priority Critical patent/US9849096B2/en
Application filed by Omniactive Health Technologies Ltd filed Critical Omniactive Health Technologies Ltd
Priority to EP14722714.4A priority patent/EP2978418A1/fr
Priority to AU2014242655A priority patent/AU2014242655A1/en
Priority to PCT/IB2014/000447 priority patent/WO2014155189A1/fr
Priority to JP2016504769A priority patent/JP2016520540A/ja
Priority to CN201480019000.4A priority patent/CN105120853A/zh
Priority to IN1208MU2013 priority patent/IN2013MU01208A/en
Priority to CA2907886A priority patent/CA2907886A1/fr
Priority to SG11201507973TA priority patent/SG11201507973TA/en
Priority to MX2015013624A priority patent/MX2015013624A/es
Publication of IN2013MU01208A publication Critical patent/IN2013MU01208A/en
Priority to PH12015502238A priority patent/PH12015502238A1/en
Priority to HK15112649.3A priority patent/HK1211836A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
IN1208MU2013 2013-03-28 2014-03-28 IN2013MU01208A (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201480019000.4A CN105120853A (zh) 2013-03-28 2014-03-28 类胡萝卜素的脑内神经保护作用
EP14722714.4A EP2978418A1 (fr) 2013-03-28 2014-03-28 Effet neuroprotecteur des caroténoïdes dans le cerveau
AU2014242655A AU2014242655A1 (en) 2013-03-28 2014-03-28 Neuroprotective effect of carotenoids in brain
PCT/IB2014/000447 WO2014155189A1 (fr) 2013-03-28 2014-03-28 Effet neuroprotecteur des caroténoïdes dans le cerveau
JP2016504769A JP2016520540A (ja) 2013-03-28 2014-03-28 脳内におけるカロテノイドの神経保護作用
US14/780,595 US9849096B2 (en) 2013-03-28 2014-03-28 Neuroprotective effect of carotenoids in brain
IN1208MU2013 IN2013MU01208A (fr) 2013-03-28 2014-03-28
MX2015013624A MX2015013624A (es) 2013-03-28 2014-03-28 Efecto neuroprotector de carotenoides en el cerebro.
SG11201507973TA SG11201507973TA (en) 2013-03-28 2014-03-28 Neuroprotective effect of carotenoids in brain
CA2907886A CA2907886A1 (fr) 2013-03-28 2014-03-28 Effet neuroprotecteur des carotenoides dans le cerveau
PH12015502238A PH12015502238A1 (en) 2013-03-28 2015-09-24 Neuroprotective effect of carotenoids in brain
HK15112649.3A HK1211836A1 (en) 2013-03-28 2015-12-23 Neuroprotective effect of carotenoids in brain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1208MU2013 IN2013MU01208A (fr) 2013-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
IN2013MU01208A true IN2013MU01208A (fr) 2015-07-03

Family

ID=50685962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1208MU2013 IN2013MU01208A (fr) 2013-03-28 2014-03-28

Country Status (12)

Country Link
US (1) US9849096B2 (fr)
EP (1) EP2978418A1 (fr)
JP (1) JP2016520540A (fr)
CN (1) CN105120853A (fr)
AU (1) AU2014242655A1 (fr)
CA (1) CA2907886A1 (fr)
HK (1) HK1211836A1 (fr)
IN (1) IN2013MU01208A (fr)
MX (1) MX2015013624A (fr)
PH (1) PH12015502238A1 (fr)
SG (1) SG11201507973TA (fr)
WO (1) WO2014155189A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145389A2 (fr) * 2014-03-28 2015-10-01 Omniactive Health Technologies Limited Effet de nutriments lipophiles sur des maladies des yeux liées au diabète
EP3265068A4 (fr) 2015-03-02 2018-10-31 OmniActive Health Technologies Limited Procédé de protection et d'amélioration de la santé du foie au moyen de compositions de méso-zéaxanthine
US10583095B2 (en) 2015-03-02 2020-03-10 Omniactive Health Technologies Limited Method for stress management and overall health status improvement and compositions used therein
US20190314442A1 (en) * 2016-02-22 2019-10-17 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases
EP3632418A4 (fr) * 2017-06-01 2021-02-24 Santen Pharmaceutical Co., Ltd. Composition destinée à la prévention et/ou à l'amélioration de dysfonctionnements cérébraux, contenant de la lutéine ou un sel de cette dernière et produit transformé issu d'une plante appartenant au genret
GB201720119D0 (en) * 2017-12-04 2018-01-17 Howard Foundation Holdings Ltd Prevention and/or treatment of neurodegenerative disease
GB201801985D0 (en) * 2018-02-07 2018-03-28 Ip Science Ltd Formulation of carotenoids
CA3095341A1 (fr) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Composition de dose fractionnee de levodopa et utilisation
SG10201900604TA (en) * 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Pre-natal beta-cryptoxanthin benefits children
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
FR3117339A1 (fr) 2020-12-16 2022-06-17 Naos Institute Of Life Science Utilisation des bactériorubérines et leurs dérivés glycosylés pour prévenir et traiter les maladies impliquant une dérégulation de l’agrégation des protéines, comme les maladies neurodégénératives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
DE19609477A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
US7081478B2 (en) 2001-06-29 2006-07-25 Chrysantis, Inc. Mixed zeaxanthin ester concentrate and uses thereof
US20060205826A1 (en) * 2005-03-09 2006-09-14 Romero Francisco J Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions
US20070238793A1 (en) 2005-12-07 2007-10-11 Lockwood Samuel F Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
WO2008099469A1 (fr) 2007-02-14 2008-08-21 Tohoku University Composition et procédé pour supprimer la péroxydation des lipides dans les érythrocytes
PT2473065E (pt) * 2009-09-02 2016-06-03 Omniactive Health Tech Ltd Uma composição de xantofila contendo pigmentos maculares e um processo para a sua preparação
CN102210662A (zh) 2010-04-06 2011-10-12 北京联合大学应用文理学院 叶黄素在制备防治脑血管疾病药物中的应用

Also Published As

Publication number Publication date
US9849096B2 (en) 2017-12-26
WO2014155189A1 (fr) 2014-10-02
EP2978418A1 (fr) 2016-02-03
US20160051490A1 (en) 2016-02-25
AU2014242655A1 (en) 2015-10-22
CA2907886A1 (fr) 2014-10-02
SG11201507973TA (en) 2015-10-29
JP2016520540A (ja) 2016-07-14
CN105120853A (zh) 2015-12-02
HK1211836A1 (en) 2016-06-03
PH12015502238A1 (en) 2016-02-01
MX2015013624A (es) 2016-06-10

Similar Documents

Publication Publication Date Title
IN2013MU01208A (fr)
BR112017012299A2 (pt) modulação imunológica
MX2017008813A (es) Polvo de coleopteros.
PH12014502336A1 (en) Iron supplementation of rice kernels
EP3318262A3 (fr) Composition pour prévenir ou traiter une maladie osseuse, l'obésité et des maladies métaboliques lipidiques
IN2014MU01128A (fr)
NZ702977A (en) 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
MX2017008815A (es) Composicion que contiene quitina y proteinas digeribles.
GB201210699D0 (en) Nutritional food
MX2015015628A (es) Acido graso del aceite de bogol para uso en suplementos y composiciones de tratamiento y piensos para animales.
WO2013028555A3 (fr) Procédés pour la perte de poids et compositions cétogènes
MX2014004507A (es) Nuevo sistema de recubrimiento.
WO2013049519A3 (fr) Compositions, kits et méthodes de supplémentation alimentaire avec des acides gras à douze atomes de carbone et des acylglycérols à douze atomes de carbone
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
WO2016190682A3 (fr) Composition pour la prévention et le traitement de maladies musculaires ou pour l'amélioration de la fonction musculaire, contenant de la morusine, du kuwanon g, ou mori cortex radicis
MX2016016995A (es) Composiciones de acido fitico, magnesio y polifenoles y su aplicacion para la prevencion de la litiasis renal oxalocalcica.
PH12017500706A1 (en) Composition containing extract or fraction of genus justicia plant
MX2016012427A (es) Suplemento alimenticio en polvo.
MX2013004371A (es) Cisteina y consumo de alimentos.
PH12017500203B1 (en) Nutritional composition for use in promoting gut and/or liver maturation and/or repair
PH12016500914A1 (en) Nutrition, exercise and cognitive development
MX349208B (es) El uso de ácido caftárico y derivados en complemento alimenticio para regular la pigmentación de la piel.
WO2011089525A3 (fr) Concentré de protéine de la graine de salvia hispanica
NZ738591A (en) Concentrated fruit juice for a marinade
MX2020009629A (es) Una composición para su uso en el tratamiento de afecciones provocadas por la carencia de calcio.